Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01286974 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.
A Phase 1 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01286974: Clinical Trial Phase 1 study, sponsored by Abbott.
NCT01286974 is a Phase 1 study that was terminated before completion, run by Abbott. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01286974, a Phase 1 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
A pharmacokinetic study to access how the body absorbs and removes linifanib in male patients with advanced solid tumors.
Primary Outcome
Blood samples for the pharmacokinetics (PK) of linifanib will be collected at designated time points.
Interventions
- DRUG [14C]linifanib
- DRUG ABT-869, linifanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Why NCT01286974 stopped before completion
NCT01286974 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which [14C]linifanib is the first listed.
NCT01286974 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01286974 about?
NCT01286974 is a clinical study titled "A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.". A pharmacokinetic study to access how the body absorbs and removes linifanib in male patients with advanced solid tumors.
What is the current status of trial NCT01286974?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2011-08. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01286974?
The interventions under investigation include: [14C]linifanib (DRUG), ABT-869, linifanib (DRUG).
Who is sponsoring clinical trial NCT01286974?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01286974's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia